First Patient Dosed in Ph 1 Trial of ATV-1601 in Patients with AKT1 E17K-mutant Solid Tumors August 12, 2025
Ph 1b trial of elraglusib, retifanlimab, and mFOLFIRINOX combo as 1L therapy in advanced pancreatic adenocarcinoma initiated August 12, 2025
Enrollment Open for 160 mg Dosing Cohort of Tuspetinib in Ph 1/2 TUSCANY Trial of 1L Triple Drug Therapy in induction-ineligible AML patients August 12, 2025
RP2D in Ph 1 Study of SENTI-202 for the Treatment of R/R Heme Malignancies, Including AML, Determined August 12, 2025
Patient death triggers switch to standard FC Lymphodepletion Regimen in the ALPHA3 Trial for Cemacabtagene Ansegedleucel (Cema-Cel) in 1L Consolidation for LBCL August 5, 2025
First Patient Dosed in Ph 3 OVATION 3 Study of IMNN-001 in Newly Diagnosed Advanced Ovarian Cancer August 5, 2025
Clinical Evaluation of SON-1010 Dose Escalation Expanded with Atezolizumab in Ovarian Cancer August 5, 2025
First patient dosed in pivotal Ph 3 AK112-305/HARMONi-8A trial of ivonescimab + docetaxel for PD-1/L1i & chemo-refractory NSCLC August 5, 2025
Targeted Enrollment Completed for Lung Cancer Ph 2 Harmonic™ Trial in Japan for LP-300 August 5, 2025
CBX-663 nominated for the treatment of a broad range of solid tumor and heme malignancies July 29, 2025
First Patient Dosed in Ph 1 Clinical Trial of EGFR-Targeting PRO-XTEN™ Dual-Masked T-Cell Engager VIR-5525 for the Treatment of Solid Tumors July 29, 2025
First Patient Dosed in COM701 Global Platform Trial in Platinum Sensitive Ovarian Cancer July 29, 2025
ALKAZAR Ph 3 Trial of Neladalkib for Patients with TKI-naïve ALK-positive NSCLC initiated July 23, 2025
Elraglusib Clinical Program Advanced in Ewing Sarcoma After Positive Ph 1 Trial Demonstrates CRs and PRs in R/R Ewing Sarcoma July 23, 2025
First Patient Enrolled in Ph 3 AK112-312/HARMONi-GI6 Trial of Ivonescimab for 1L Metastatic CRC July 23, 2025
First patient dosed in NCI-sponsored pilot study of Pidnarulex (CX-5461) PD in patients with advanced solid tumors July 23, 2025
Dose Level 1 of ANGELICA TRIAL completed; Proceeding to Dose Level 2 in Patients with Advanced Solid Tumors or Heme Malignancies July 23, 2025
CRC Cohort of Ph 2 Trial of PDS01ADC Met Criteria for Expansion to Stage 2 Following Positive Stage 1 Results July 15, 2025
Enrollment completed in Ph 3 UTOPIA Trial of UGN-103 for the Treatment of Recurrent Low-Grade Intermediate-Risk NMIBC July 15, 2025
First patient dosed in the Ph 1 portion of Ph 1/2 trial of AVZO-1418/DB-1418 in patients with advanced solid tumors July 15, 2025
